poster

Physician Perspective on Idiopathic Hypersomnia: Awareness, Diagnosis, and Impact on Patients

This online survey assessed US physicians’ familiarity with idiopathic hypersomnia and understanding of the diagnostic process and impact on patients’ lives. Most physicians agreed idiopa...

10/26/2023

Pharmaceutical Pipeline of BI 1358894: Clinical Evidence for an Emerging Drug for the Treatment of Mental Health Conditions

Dysregulated emotional processing and overwhelming negative emotions are core symptoms of disorders such as posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) and ar...

10/26/2023

Pharmacogenomic Testing in Depression Care: Can Curriculum Based Online Education Improve Provider Knowledge, Competence, and Confidence?

Many clinicians are unaware of the evidence for pharmacogenomic (PGx) testing in depression care and are uncertain as to how to incorporate this modality into clinical decision making. Th...

10/26/2023

Pharmacokinetic Simulations of Aripiprazole 2-Month Ready-To-Use Long-Acting Injectable to Inform Administration in Adult Patients With Schizophrenia or Bipolar-I Disorder

Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a novel long-acting injectable formulation of aripiprazole for gluteal administration once every 2 months. Simulations conducte...

10/26/2023

Pharmacokinetics and Safety of RYKINDO® (Risperidone) for Extended-Release Injectable Suspension, a Novel Long-Acting Injectable Risperidone, in Patients With Schizophrenia and/or Schizoaffective Disorder

This randomized, open-label, relative bioavailability study comparatively evaluated the pharmacokinetics and safety of RYKINDO®, a novel long-acting risperidone administered biweekly (Q2W...

10/26/2023

Physician Assistants/Associates Burnout and Intention to Leave Principal Clinical Position: A National Cross-Sectional Analysis

We undertook a national study to evaluate and quantify burnout levels among the PA workforce. The study’s findings highlight that approximately a third of PAs experience at least one symp...

10/26/2023

Opioid Antagonists: Clinical Utility, Pharmacology, and Safety and Tolerability

Pharmacology, clinical uses, and safety/tolerability of FDA-approved opioid antagonists are reviewed. Opioid antagonists treat opioid overdose, alcohol/opioid use disorder, and opioid-ind...

10/26/2023

Outcomes From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia

OASIS was an observational study that evaluated real-world outcomes of atypical long-acting injectable (aLAI) antipsychotics in patients with schizophrenia. Overall, CGI-S scores at basel...

10/26/2023

Patient Perspective on Idiopathic Hypersomnia: Impact on Quality of Life and Satisfaction With the Diagnostic Process and Management

This study assessed symptoms, impact, diagnosis, and management of idiopathic hypersomnia in US patients surveyed online. Most respondents reported they had been misdiagnosed before recei...

10/26/2023

Patient Perspectives of Meaningful Change in Major Depressive Disorder

Findings from qualitative interviews with 19 US adult patients with major depressive disorder (MDD) highlighted the episodic and heterogeneous nature of MDD, as well as the importance of ...

10/26/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products